/
Psychiatry
Bipolar Disorder
35
Pipeline Programs↗
31
Active Trials↗
29
Companies Involved↗
Bipolar Disorder is a moderately active landscape with 35 programs across 29 companies. The most active players are Nanjing Chia-tai Tianqing Pharmaceutical, Vanda Pharmaceuticals, Otsuka. 4 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical27
Phase 1
No programs
Phase 24
Phase 34
Approved
No programs
Analysis
Modality Breakdown
94%
Small molecule
32 of 34 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 34 classified programs, each share of the total. Modality classified for 97% of 35 pipeline programs.
Analysis
Trial Status
258
clinical trials
Completed169 · 66%
Terminated25 · 10%
Unknown status24 · 9%
Recruiting22 · 9%
Withdrawn9 · 3%
Not yet recruiting7 · 3%
Other2 · 1%
Clinical Trials
Trial Activity
258 trials
Physical Exercise for Cognitive Rehabilitation of Patients With Bipolar Affective Disorder: a Controlled and Randomized Study
Recruiting·—·Preclinical·NCT06560749·72 enrolled
Page 1 of 18
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)